Gossamer Bio’s stock falls 64% on findings for Phase 2 study for hypertension drug

Shares of Gossamer Bio Inc. GOSS, -75.40% plunged 64.5% in premarket trading on Tuesday after Wall Street analysts questioned the performance of the company’s experimental hypertension drug in a...